Maria Sharapova banned: ITF statement in full as star is handed two-year ban following failed drugs test

The former world number one admitted to taking meldonium for 10 years after being recommended to do so by a family-approved doctor on medical grounds

(Getty Images)

Former Wimbledon champion Maria Sharapova been handed a two-year ban after failing an anti-doping test at the Australian Open in January.

The 29-year-old Russian admitted to taking meldonium, a heart disease treatment, for a period of time which overlapped the 1 January 2016 cut-off date, when it was added to the World Anti-Doping Agency’s (Wada) banned list. The International Tennis Federation (ITF) released a statement (below) on Wednesday announcing the news.

Sharapova, the former world number one, admitted to taking meldonium for 10 years after being recommended to do so by a family-approved doctor on medical grounds.

The ITF confirmed that Sharapova failed the drug test on the same day as her quarter-final defeat by Serena Williams in Melbourne, and she was informed of the failed test via letter in March.

All athletes were informed that the drug had been added to the banned list at the beginning of the calendar year but Sharapova insists she only knew the drug by the name mildronate.

The statement in full

An Independent Tribunal appointed under Article 8.1 of the 2016 Tennis Anti-Doping Programme (the "Programme") has found that Maria Sharapova committed an Anti-Doping Rule Violation under Article 2.1 of the Programme and as a consequence has disqualified the affected results and imposed a period of ineligibility of two years, commencing on 26 January 2016.

Ms. Sharapova, a 29-year-old player from Russia, provided a urine sample on 26 January 2016, after her quarter-final match at the 2016 Australian Open in Melbourne, Australia. That sample was sent to the WADA-accredited laboratory in Montreal, Canada for analysis, and was found to contain meldonium, which is a metabolic modulator that is included under section S4 (Hormone and Metabolic Modulators) of the 2016 WADA Prohibited List, and therefore is also prohibited under the Programme.

On 2 March 2016, Ms. Sharapova was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample). She promptly admitted that she had committed the Anti-Doping Rule Violation charged, and asked for a hearing before an Independent Tribunal in accordance with Article 8 of the Programme to determine the consequences to be imposed on her for that violation.

At a two-day hearing on 18-19 May 2016, the Independent Tribunal received evidence and heard legal arguments from both parties, and subsequently issued a reasoned decision on 8 June, which is available below. The Independent Tribunal determined that (1) Ms. Sharapova should serve a period of ineligibility of two years; (2) due to her prompt admission of her violation, that period of ineligibility should be back-dated under Article 10.10.3(b) of the Programme to commence from 26 January 2016 (the date of sample collection) and so should end at midnight on 25 January 2018; and (3) her results at the 2016 Australian Open should be disqualified, with resulting forfeiture of the ranking points and prize money that she won at that event.

The Tennis Anti-Doping Programme applies to all players competing at Grand Slam tournaments and events sanctioned by the ITF, ATP, and WTA. Players are tested for substances prohibited by the World Anti-Doping Agency and, upon a finding that an Anti-Doping Rule Violation has been committed, sanctions are imposed under the Programme in compliance with the requirements of the World Anti-Doping Code.